Changes in the prevalence of human papillomavirus following a national bivalent human papillomavirus vaccination programme in Scotland: a 7-year cross-sectional study.

[1]  H. Cubie,et al.  Reduction in colposcopy workload and associated clinical activity following human papillomavirus (HPV) catch‐up vaccination programme in Scotland: an ecological study , 2017, BJOG : an international journal of obstetrics and gynaecology.

[2]  H. Kitchener,et al.  Will cervical screening remain cost‐effective in women offered the next generation nonavalent HPV vaccine? Results for four developed countries , 2016, International journal of cancer.

[3]  C. Tanton,et al.  Population-Level Effects of Human Papillomavirus Vaccination Programs on Infections with Nonvaccine Genotypes , 2016, Emerging infectious diseases.

[4]  A. Mihályi,et al.  Response letter regarding the letter to the editors by Brown et al. , 2016, Human vaccines & immunotherapeutics.

[5]  Martin Steinau,et al.  Prevalence of HPV After Introduction of the Vaccination Program in the United States , 2016, Pediatrics.

[6]  M. Schiffman,et al.  Triage of HPV positive women in cervical cancer screening. , 2016, Journal of clinical virology : the official publication of the Pan American Society for Clinical Virology.

[7]  S. Cotton,et al.  HPV immunisation and cervical screening—confirmation of changed performance of cytology as a screening test in immunised women: a retrospective population-based cohort study , 2016, British Journal of Cancer.

[8]  M. Poljak,et al.  HPV-FASTER: broadening the scope for prevention of HPV-related cancer , 2016, Nature Reviews Clinical Oncology.

[9]  S. Beddows,et al.  Continuing reductions in HPV 16/18 in a population with high coverage of bivalent HPV vaccination in England: an ongoing cross-sectional study , 2016, BMJ Open.

[10]  C. Robertson,et al.  Human Papillomavirus Prevalence and Herd Immunity after Introduction of Vaccination Program, Scotland, 2009–2013 , 2016, Emerging infectious diseases.

[11]  E. Unger,et al.  Reduction in Human Papillomavirus Vaccine Type Prevalence Among Young Women Screened for Cervical Cancer in an Integrated US Healthcare Delivery System in 2007 and 2012-2013. , 2015, The Journal of infectious diseases.

[12]  S. Garland,et al.  Human papillomavirus in young women with Chlamydia trachomatis infection 7 years after the Australian human papillomavirus vaccination programme: a cross-sectional study. , 2015, The Lancet. Infectious diseases.

[13]  M. Poljak,et al.  Which high-risk HPV assays fulfil criteria for use in primary cervical cancer screening? , 2015, Clinical microbiology and infection : the official publication of the European Society of Clinical Microbiology and Infectious Diseases.

[14]  C. Tanton,et al.  Population-level impact and herd effects following human papillomavirus vaccination programmes: a systematic review and meta-analysis. , 2015, The Lancet. Infectious diseases.

[15]  J. Dillner,et al.  Are 20 human papillomavirus types causing cervical cancer? , 2014, The Journal of pathology.

[16]  A. Fiander,et al.  Type-specific HPV prevalence in invasive cervical cancer in the UK prior to national HPV immunisation programme: baseline for monitoring the effects of immunisation , 2014, Journal of Clinical Pathology.

[17]  J. Dillner,et al.  Change in Population Prevalences of Human Papillomavirus after Initiation of Vaccination: The High-Throughput HPV Monitoring Study , 2014, Cancer Epidemiology, Biomarkers & Prevention.

[18]  H. Cubie,et al.  Reduction of low- and high-grade cervical abnormalities associated with high uptake of the HPV bivalent vaccine in Scotland , 2014, British Journal of Cancer.

[19]  H. Cubie,et al.  Introduction and sustained high coverage of the HPV bivalent vaccine leads to a reduction in prevalence of HPV 16/18 and closely related HPV types , 2014, British Journal of Cancer.

[20]  J. Berkhof,et al.  Efficacy of HPV-based screening for prevention of invasive cervical cancer: follow-up of four European randomised controlled trials , 2014, The Lancet.

[21]  H. Cubie,et al.  Estimation of HPV prevalence in young women in Scotland; monitoring of future vaccine impact , 2013, BMC Infectious Diseases.

[22]  C. Robertson,et al.  Achieving high and equitable coverage of adolescent HPV vaccine in Scotland , 2013, Journal of Epidemiology & Community Health.

[23]  M. Jit,et al.  Cross-protective efficacy of two human papillomavirus vaccines: a systematic review and meta-analysis. , 2012, The Lancet. Infectious diseases.

[24]  Masha Fridman,et al.  Early effect of the HPV vaccination programme on cervical abnormalities in Victoria, Australia: an ecological study , 2011, The Lancet.

[25]  H. Cubie,et al.  Distribution of HPV types associated with cervical cancers in Scotland and implications for the impact of HPV vaccines , 2010, British Journal of Cancer.

[26]  J. Cuzick,et al.  Chapter 20: Issues in planning cervical cancer screening in the era of HPV vaccination. , 2006, Vaccine.

[27]  A. Trevisan,et al.  Prevalence of childhood exanthematic disease antibodies in paramedical students: need of vaccination. , 2006, Vaccine.

[28]  David R. Scott,et al.  The elevated 10-year risk of cervical precancer and cancer in women with human papillomavirus (HPV) type 16 or 18 and the possible utility of type-specific HPV testing in clinical practice. , 2005, Journal of the National Cancer Institute.